Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure

Cairo University60 enrolled

Overview

Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Dexmedetomidine

Interventions

Dexmedetomidine with MannitolDRUG

receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol

Mannitol (20%)DRUG

receive 0.5 g/kg of mannitol

Eligibility

Sex: ALLMin age: 40 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: ASA I-II Patients scheduled for elective robot-assisted laparoscopic prostatectomy Exclusion Criteria: * • ASA physical status \> II * Cardiac patients * Cerebrovascular disease * Glaucoma * Hepatic failure * Renal failure * History of anaphylactic reaction to dexmedetomidine or mannitol * Hemodynamic instability * Cannot measure ONSD for example due to ophthalmological problems. * Any cause of preoperative increase in ICP for example intracranial space occupying lesions.

Locations (1)

facility of medicine Cairo university

Cairo, Egypt

Outcomes

Primary Outcomes

optic nerve sheath diameter

Time frame: 90 minutes

Secondary Outcomes

Postoperative neurologic complications

Time frame: 24 HOURS

Postoperative cardiac complications

Time frame: 24 hours

Duration of hospital stay

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.